Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.

Journal of pharmacokinetics and pharmacodynamics - 1 Jun 2022

Tanveer Ayesha, Hussain Khalid, Tasneem Hirra, Arif Iqra, Rashid Memoona, Abbas Nasir, Shamim Rahat, Shah Pervaiz A, Bukhari Nadeem Irfan

Abstract excerpt

The concomitant use of herbal products and synthetic drugs necessitates the assessment of their interaction potentials. The herbal hepatoprotective medicine, silybin A inhibits cytochrome P450 (CYP) 2C9 and 3A4 enzymes, thus, may interact with the drugs that are substrates of CYP2C9 and 3A4, such as losartan. The three most prominent genotypes, expressed by CYP2C9 are the CYP2C9*1/*1, CYP2C9*1/*2 and CYP2C9*1/*3....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C9
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Losartan

Share to Models, Biological

Source

Identifiers

PMID: 35061161
DOI: 10.1007/s10928-022-09804-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.PMID 35061161Read ↗

Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.Semantic proximity Read ↗

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.Semantic proximity Read ↗

Cytochrome P450 and P‐Glycoprotein‐Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable DiseasesSemantic proximity Read ↗

Herb-drug interactions: methods to identify potential influence of genetic variations in genes encoding drug metabolizing enzymes and drug transporters.Semantic proximity Read ↗

Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.Semantic proximity Read ↗

The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silibinin.Semantic proximity Read ↗

Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.Semantic proximity Read ↗

Flavonoids As CYP3A4 Inhibitors In VitroSemantic proximity Read ↗

Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide.Semantic proximity Read ↗

<i>In vivo</i>assessment of herb–drug interactions: Possible utility of a pharmacogenetic approach?Semantic proximity Read ↗

Insights into Intestinal P-glycoprotein Function using Talinolol: A PBPK Modeling ApproachSemantic proximity Read ↗

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.